Mouse anti Human HLA-DR, conjugated with FITCCatalog number: 0DR2
HLA-DR is used for the identification of human B cell and T cell subsets associated with approximately 10% of peripheral blood lymphocytes 28-34,000 M.W. surface antigen, and is present in low density on monocytes and macrophages.
Synonyms: HLA-DR* FITC
Derived from the hybridization of mouse NS-1/1-Ag4 myeloma cells with spleen cells of BALB/c mice immunized with human lymphoblastoid B-cell line RPMI 8866
Provided as solution in phosphate buffered saline with 0.08% sodium azide and 0.2% carrier protein
Product Form: FITC
Purification Method: Protein A/G Chromatography
Concentration: Titered for flow cytometry
Flow Cytometry PBMC: Add 10 µl of MAB/10^6 PBMC in 100 µl PBS. Mix gently and incubate for 15 minutes at 2º to 8ºC. Wash twice with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. WHOLE BLOOD: Add10 µl of MAB/100 µl of whole blood. Mix gently and incubate for 15 minutes at room temperature 20ºC. Lyse the whole blood. Wash once with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. See instrument manufacturer’s instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.
Functional Analysis: Flow Cytometry Staining
Product should be stored at 4-8ºC. DO NOT FREEZE
Product Stability: See expiration date on vial
Shipping Conditions: Ship at ambient temperature
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
1. IL-4 and granulocyte-macrophage colony-stimulating factor selectively increase HLA-DR and HLA-DP antigens but not HLA-DQ antigens on human monocytes. Gerrard T.L., Dyer D.R., Mostowski H.S., J. Immunol. 1990 June, 1;144(12): 4670-4. 2. Structural requirements for pairing of alpha and beta chains in HLA-DR and HLA-DP molecules. Karp D.R., Teletski C.L., Jaraquemada D., Maloy W.L., Coligan J.E., Long E.O., J. Exp.. Med. 1990 March ;171(3):615-28. 3. Trans-activation of HLA-DR gene by hepatitis B virus X gene product. Hu K.Q., Vierling J.M., Siddiqui A., Proc. Natl. Acad. Sci. USA 1990 SEPT.; 87(18):7140-4. 4. Purified primitive human hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma. Verfaillie C., Blakolmer K., McGlave P., J. Exp. Med. 1990 Aug.: 172(2):509-2. 5. Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+ CD8+ DR+ CD25- T cell population. Pantaleo G., Keonig S., Baseler M., Lane H.C., Fauci A.S., J. Immunol. 1990 Mar ; 144(5):1696-704. 6. Increased circulating HLA-DR+ CD4+ T cells in systemic lupus erythematosus: alterations associated with prednisolone therapy. Raziuddin S., Nur M.A., al-Wabel A.A., Scand. J. Immunol. 1990 Feb.:31(2):139-45.
Database Name: UniProt
Accession Number: P04233
Safety Datasheet(s) for this product:
Mouse anti Human HLA-DR, conjugated with FITC
$205.00Add To Cart